OasisLMS

Join Digital Education Committee Chair and podcast host Michael S. Lloyd, MD, FHRS, and his guests Kelvin C. Chua, MBBS, MD, FHRS, CEPS-A, and Rahul N Doshi, MD, FHRS, for this week's Lead episode, which was recorded live at APHRS 2025 in Kyoto, Japan.

This discussion will review recent evidence on the feasibility and safety of pulsed field ablation (PFA) for coronary sinus and left atrial appendage isolation, as well as mitral isthmus ablation, focusing on both acute and chronic outcomes. Panelists will examine procedural considerations, lesion durability, and safety signals highlighted in the study, and explore how these findings may inform evolving ablation strategies for complex atrial arrhythmias.

• Summarize the acute and chronic feasibility and safety outcomes of pulsed field ablation (PFA) for coronary sinus isolation, left atrial appendage isolation, and mitral isthmus ablation as reported in the study.

• Evaluate procedural techniques and lesion durability considerations associated with using PFA in anatomically complex atrial structures.

• Assess the potential clinical implications of these findings for incorporating PFA into ablation strategies for complex atrial arrhythmias, including patient selection and risk mitigation.

Article Authors

Vincenzo Mirco La Fazia, MD, Sanghamitra Mohanty, MD, Carola Gianni, MD, Elio Zito, MD, Nicola Pierucci, MD, Giuseppe Stifano, MD, Preem Geeta Torlapati, MD, Domenico G. Della Rocca, MD, Weeranun Dechyapirom Bode, MD, J. David Burkhardt, MD, Rodney Horton, MD, Amin Al-Ahmad, MD, Luigi Di Biase, Andrea Natale, MD

Podcast Contributors

Michael S. Lloyd, MD, FHRS

Kelvin C. Chua, MBBS, MD, FHRS, CEPS-A

Rahul N Doshi, MD, FHRS

All relevant financial relationships have been mitigated.

Host and Contributor Disclosure(s):

K.C. Chua

•Nothing to disclose.

 

Staff Disclosure(s) (note: HRS staff are NOT in control of educational content. Disclosures are provided solely for full transparency to the learner):

S. Sailor: No relevant financial relationships with ineligible companies to disclose.